Drug Trial Radar · NCT05607537
A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants
Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Oct 17, 2022
Primary completion
Aug 31, 2023
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the absolute bioavailability of E7386 following a single oral dose of E7386 as a one 40 milligram (mg) immediate release (IR) tablet and concomitant intravenous (IV) microdose of (14C)E7386 (100 mcg \[microgram\]) solution for Part 1 and to determine the pharmacokinetic (PK) and excretion of E7386 following a single 40 mg powder in capsule (PIC) oral administration of (14C)E7386 for Part 2.
Conditions
- Healthy Volunteers
Interventions
E7386 TabletDrug
E7386 40 mg tablet.
(14C)E7386 CapsuleDrug
(14C)E7386 40 mg capsule.
(14C)E7386Drug
(14C)E7386 administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, %F: Percent Absolute Oral Bioavailability for (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, Cmax: Maximum Observed Plasma Concentration for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, Tlag: Time Delay Between Drug Administration and the Onset of Absorption for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, Tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, AUC(0-12h): Area Under the Plasma Concentration-time Curve From Time Zero to 12 hours Post-dose for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 12 hours post-dose
- Part 1, AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 hours Post-dose for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 24 hours post-dose
- Part 1, AUC(0-last): Area Under the Plasma Concentration-time Curve from Time 0 to Time of the Last Measurable Concentration for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, t1/2: Apparent Terminal Elimination Phase Half-life for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, MRT: Mean Residence Time of (14C)E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, CL: Total Clearance of (14C)E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, CL/F: Apparent Total Body Clearance of E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, Vss: Volume of Distribution at Steady State of (14C)E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, Vz/F: Apparent Volume of Distribution at Terminal Phase of E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 1, Fa: Percentage of Absorbed Dose Using Total Radioactivity in UrineTime frame: Pre-dose (0 hour) up to 96 hours post-dose
- Part 2, Cmax: Maximum Observed Concentration for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, Tlag: Time Delay Between Drug Administration and the Onset of Absorption for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, Tmax: Time to Reach Maximum Observed Concentration (Cmax) for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, AUC(0-12h): Area Under the Concentration-time Curve From Time Zero to 12 hours Post-dose for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 12 hours post-dose
- Part 2, AUC(0-24h): Area Under the Concentration-time Curve From Time Zero to 24 hours Post-dose for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 24 hours post-dose
- Part 2, AUC(0-last): Area Under the Concentration-time Curve from Time 0 to Time of the Last Measurable Concentration for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, AUC(0-inf): Area Under the Concentration-time Curve From Time Zero to Infinite Time for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, t1/2: Apparent Terminal Elimination Phase Half-life for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, CL/F: Apparent Total Body Clearance of E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, Vz/F: Apparent Volume of Distribution at Terminal Phase of E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
- Part 2, feu: Percentage of Administered Radioactive Dose Excreted in Urine for Total RadioactivityTime frame: Day -1 (Baseline) up to Day 49
- Part 2, Cumulative feu(0-tlast): Cumulative Radioactive Dose Excreted in Urine From Time 0 to Time of the Last Measurable ConcentrationTime frame: Day -1 (Baseline) up to Day 49
- Part 2, fef: Percentage of Total Radioactivity Recovered in Feces Relative to the Administered Radioactive DoseTime frame: Day -1 (Baseline) up to Day 49
- Part 2, Cumulative fef(0-tlast): Cumulative Radioactive Dose Excreted in Feces From Time 0 to Time of the Last Measurable ConcentrationTime frame: Day -1 (Baseline) up to Day 49
- Part 2, feu+ef: Percentage of Total Radioactivity Recovered in Combined Urine and Feces Relative to the Administered Radioactive DoseTime frame: Day -1 (Baseline) up to Day 49
- Part 2, Cumulative feu+ef(0-tlast): Cumulative Radioactive Dose excreted in Combined Excreta (Urine and Feces) From Time Zero to Time of the Last Measurable ConcentrationTime frame: Day -1 (Baseline) up to Day 49
- Part 2, Fa: Percentage of Absorbed Dose Using Total Radioactivity in UrineTime frame: Day -1 (Baseline) up to Day 49
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Labcorp Clinical Research Unit
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.